Monitoring and Improving Adherence to Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia: A Systematic Review

References

• Hoglund M, Sandin F, Simonsson B. Epidemiology of chronic myeloid leukaemia: an update. Ann Hematol. 2015;94(Suppl 2):S241–247. doi:10.1007/s00277-015-2314-2
   PubMed Web of Science ®Google Scholar
• Hochhaus A, Baccarani M, Silver RT, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020;34(4):966–984. doi:10.1038/s41375-020-0776-2
   PubMed Web of Science ®Google Scholar
• Noens L, Hensen M, Kucmin-Bemelmans I, Lofgren C, Gilloteau I, Vrijens B. Measurement of adherence to BCR-ABL inhibitor therapy in chronic myeloid leukemia: current situation and future challenges. Haematologica. 2014;99(3):437–447. doi:10.3324/haematol.2012.082511
   PubMed Web of Science ®Google Scholar
• Chen TC, Chen LC, Huang YB, Chang CS. Imatinib adherence associated clinical outcomes of chronic myeloid leukaemia treatment in Taiwan. Int J Clin Pharm. 2014;36(1):172–181. doi:10.1007/s11096-013-9876-7
   PubMed Web of Science ®Google Scholar
• Darkow T, Henk HJ, Thomas SK, et al. Treatment interruptions and non-adherence with imatinib and associated healthcare costs: a retrospective analysis among managed care patients with chronic myelogenous leukaemia. PharmacoEconomics. 2007;25(6):481–496. doi:10.2165/00019053-200725060-00004
   PubMed Web of Science ®Google Scholar
• Marin D, Bazeos A, Mahon FX, et al. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol. 2010;28(14):2381–2388. doi:10.1200/JCO.2009.26.3087
   PubMed Web of Science ®Google Scholar
• Efficace F, Baccarani M, Breccia M, et al. Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population. Blood. 2011;118(17):4554–4560. doi:10.1182/blood-2011-04-347575
   PubMed Web of Science ®Google Scholar
• Heiney SP, Sorrell M, Sheng J, et al. Interventions to Improve Adherence to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: a Systematic Review. Am J Clin Oncol. 2021;44(6):291–298. doi:10.1097/COC.0000000000000818
   Web of Science ®Google Scholar
• Dusetzina SB, Winn AN, Abel GA, Huskamp HA, Keating NL. Cost sharing and adherence to tyrosine kinase inhibitors for patients with chronic myeloid leukemia. J Clin Oncol. 2014;32(4):306–311. doi:10.1200/JCO.2013.52.9123
   PubMed Web of Science ®Google Scholar
• Shen C, Zhao B, Liu L, Shih YT. Adherence to tyrosine kinase inhibitors among Medicare Part D beneficiaries with chronic myeloid leukemia. Cancer. 2018;124(2):364–373. doi:10.1002/cncr.31050
   Web of Science ®Google Scholar
• Wu EQ, Guerin A, Yu AP, Bollu VK, Guo A, Griffin JD. Retrospective real-world comparison of medical visits, costs, and adherence between nilotinib and dasatinib in chronic myeloid leukemia. Curr Med Res Opin. 2010;26(12):2861–2869. doi:10.1185/03007995.2010.533648
   PubMed Web of Science ®Google Scholar
• Yood MU, Oliveria SA, Cziraky M, Hirji I, Hamdan M, Davis C. Adherence to treatment with second-line therapies, dasatinib and nilotinib, in patients with chronic myeloid leukemia. Curr Med Res Opin. 2012;28(2):213–219. doi:10.1185/03007995.2011.649849
   PubMed Web of Science ®Google Scholar
• Trivedi D, Landsman-Blumberg P, Darkow T, Smith D, McMorrow D, Mullins CD. Adherence and persistence among chronic myeloid leukemia patients during second-line tyrosine kinase inhibitor treatment. J Managed Care Specialty Pharm. 2014;20(10):1006–1015. doi:10.18553/jmcp.2014.20.10.1006
   PubMed Web of Science ®Google Scholar
• Latremouille-Viau D, Guerin A, Gagnon-Sanschagrin P, Dea K, Cohen BG, Joseph GJ. Health Care Resource Utilization and Costs in Patients with Chronic Myeloid Leukemia with Better Adherence to Tyrosine Kinase Inhibitors and Increased Molecular Monitoring Frequency. J Managed Care Specialty Pharm. 2017;23(2):214–224. doi:10.18553/jmcp.2017.23.2.214
   PubMed Web of Science ®Google Scholar
• Rosenberg SM, Petrie KJ, Stanton AL, Ngo L, Finnerty E, Partridge AH. Interventions to Enhance Adherence to Oral Antineoplastic Agents: a Scoping Review. J Natl Cancer Inst. 2020;112(5):443–465. doi:10.1093/jnci/djz244
   PubMedGoogle Scholar
• Hewison A, Atkin K, McCaughan D, et al. Experiences of living with chronic myeloid leukaemia and adhering to tyrosine kinase inhibitors: a thematic synthesis of qualitative studies. Eur J Oncol Nurs. 2020;45:101730. doi:10.1016/j.ejon.2020.101730
   PubMed Web of Science ®Google Scholar
• Cordova MJ, Giese-Davis J, Golant M, et al. Mood disturbance in community cancer support groups. The role of emotional suppression and fighting spirit. J Psychosom Res. 2003;55(5):461–467. doi:10.1016/S0022-3999(03)00510-5
   PubMed Web of Science ®Google Scholar
• Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.
   PubMed Web of Science ®Google Scholar
• Campbell M, McKenzie JE, Sowden A, et al. Synthesis without meta-analysis (SWiM) in systematic reviews: reporting guideline. BMJ. 2020;368:l6890.
   PubMed Web of Science ®Google Scholar
• IBMCorp Ibm SJA, NY: IBM Corp. Statistics for Windows, Version 25.0; 2017.
   Google Scholar
• Koo TK, Li MY. A Guideline of Selecting and Reporting Intraclass Correlation Coefficients for Reliability Research. J Chiropr Med. 2016;15(2):155–163. doi:10.1016/j.jcm.2016.02.012
   PubMed Web of Science ®Google Scholar
• Portney LG, Watkins MP. Foundations of Clinical Research: Applications to Practice. Vol. 892. Pearson/Prentice Hall Upper Saddle River, NJ; 2009.
   Google Scholar
• Sterne JAC, Savović J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898. doi:10.1136/bmj.l4898
   PubMed Web of Science ®Google Scholar
• Wells G, Shea B, O’Connell J. The Newcastle-Ottawa Scale (NOS) for Assessing The Quality of Nonrandomised Studies in Meta-analyses. Ottawa Health Res Inst Web Site. 2014;7.
   Google Scholar
• Downes MJ, Brennan ML, Williams HC, Dean RS. Development of a critical appraisal tool to assess the quality of cross-sectional studies (AXIS). BMJ Open. 2016;6(12):e011458.
   PubMed Web of Science ®Google Scholar
• Deeks JJ, Higgins JP, Altman DG; Group obotCSM.Analysing data and undertaking meta-analyses. Cochrane Handbook for Systematic Reviews of Interventions; 2019. 241–284.
   Google Scholar
• Tan BK, Chua SS, Chen LC, Chang KM, Balashanker S, Bee PC. Efficacy of a medication management service in improving adherence to tyrosine kinase inhibitors and clinical outcomes of patients with chronic myeloid leukaemia: a randomised controlled trial. Sup Care Cancer. 2020;28(7):3237–3247. doi:10.1007/s00520-019-05133-0
   Web of Science ®Google Scholar
• Kekale M, Soderlund T, Koskenvesa P, Talvensaari K, Airaksinen M. Impact of tailored patient education on adherence of patients with chronic myeloid leukaemia to tyrosine kinase inhibitors: a randomized multicentre intervention study. J Adv Nurs. 2016;72(9):2196–2206. doi:10.1111/jan.12978
   Web of Science ®Google Scholar
• Dennison T, Deal AM, Foster M, Valgus J, Muluneh B, Pharmacist-Led Oral A. Chemotherapy Program’s Impact on Chronic Myeloid Leukemia Patient Satisfaction, Adherence, and Outcomes. J Adv Practitioner Oncol. 2021;12(2):148–157.
   Google Scholar
• Sawicki C, Friend KE, Patel R, Polinski JM, Singh S. Two-Way Clinical Messaging in a CML Specialty Pharmacy Service Model. J Managed Care Specialty Pharm. 2019;25(11):1290–1296. doi:10.18553/jmcp.2019.25.11.1290
   Web of Science ®Google Scholar
• Lam MS, Cheung N. Impact of oncology pharmacist-managed oral anticancer therapy in patients with chronic myelogenous leukemia. J Oncol Pharmacy Pract. 2016;22(6):741–748. doi:10.1177/1078155215608523
   Web of Science ®Google Scholar
• Moon JH, Sohn SK, Kim SN, et al. Patient counseling program to improve the compliance to imatinib in chronic myeloid leukemia patients. Med Oncol. 2012;29(2):1179–1185. doi:10.1007/s12032-011-9926-8
   PubMed Web of Science ®Google Scholar
• Leader A, Benyamini N, Gafter-Gvili A, et al. Effect of Adherence-enhancing Interventions on Adherence to Tyrosine Kinase Inhibitor Treatment in Chronic Myeloid Leukemia (TAKE-IT): a Quasi-experimental Pre-Post Intervention Multicenter Pilot Study. Clin Lymphoma Myeloma Leuk. 2018;18(11):e449–e461. doi:10.1016/j.clml.2018.06.026
   Web of Science ®Google Scholar
• Santoleri F, Lasala R, Logreco A, Ranucci E, Costantini A. Using a treatment diary to improve the medication adherence in patients with chronic myeloid leukaemia. J Oncol Pharmacy Pract. 2019;25(5):1035–1041. doi:10.1177/1078155218759184
   Web of Science ®Google Scholar
• Lam MS, Cheung N. Impact of oncology pharmacist-managed oral anticancer therapy in patients with chronic myelogenous leukemia. J Oncol Pharmacy Pract. 2015;2:154.
   Google Scholar
• Moulin SM, Eutrópio FJ, Souza JO, Busato FO, Olivieri DN, Tadokoro CE. The role of clinical pharmacists in treatment adherence: fast impact in suppression of chronic myeloid leukemia development and symptoms. Sup Care Cancer. 2017;25(3):951–955. doi:10.1007/s00520-016-3486-6
   Web of Science ®Google Scholar
• Craig P, Dieppe P, Macintyre S, et al. Developing and evaluating complex interventions: the new Medical Research Council guidance. BMJ. 2008;337:a1655. doi:10.1136/bmj.a1655
   PubMed Web of Science ®Google Scholar
• Michie S, van Stralen MM, West R. The behaviour change wheel: a new method for characterising and designing behaviour change interventions. Implement Sci. 2011;6:42. doi:10.1186/1748-5908-6-42
   PubMed Web of Science ®Google Scholar
• Tan BK, Tan SB, Chen LC, et al. Medication-related issues associated with adherence to long-term tyrosine kinase inhibitors for controlling chronic myeloid leukemia: a qualitative study. Patient Prefer Adherence. 2017;11:1027–1034. doi:10.2147/PPA.S132894
   PubMed Web of Science ®Google Scholar
• Gater A, Heron L, Abetz-Webb L, et al. Adherence to oral tyrosine kinase inhibitor therapies in chronic myeloid leukemia. Leuk Res. 2012;36(7):817–825. doi:10.1016/j.leukres.2012.01.021
   Web of Science ®Google Scholar